1 Study Coverage 1.1 Drugs for Neuromyelitis Optica Product Introduction 1.2 Global Drugs for Neuromyelitis Optica Outlook 2017 VS 2022 VS 2028 1.2.1 Global Drugs for Neuromyelitis Optica Sales in US$ Million for the Year 2017-2028 1.2.2 Global Drugs for Neuromyelitis Optica Sales in Volume for the Year 2017-2028 1.3 United States Drugs for Neuromyelitis Optica Outlook 2017 VS 2022 VS 2028 1.3.1 United States Drugs for Neuromyelitis Optica Sales in US$ Million for the Year 2017-2028 1.3.2 United States Drugs for Neuromyelitis Optica Sales in Volume for the Year 2017-2028 1.4 Drugs for Neuromyelitis Optica Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.4.1 The Market Share of United States Drugs for Neuromyelitis Optica in Global, 2017 VS 2022 VS 2028 1.4.2 The Growth Rate of Drugs for Neuromyelitis Optica Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.5 Drugs for Neuromyelitis Optica Market Dynamics 1.5.1 Drugs for Neuromyelitis Optica Industry Trends 1.5.2 Drugs for Neuromyelitis Optica Market Drivers 1.5.3 Drugs for Neuromyelitis Optica Market Challenges 1.5.4 Drugs for Neuromyelitis Optica Market Restraints 1.6 Study Objectives 1.7 Years Considered 2 Market by Type 2.1 Drugs for Neuromyelitis Optica Market Segment by Type 2.1.1 Glucocorticoids 2.1.2 Immunotherapies 2.1.3 Other 2.2 Global Drugs for Neuromyelitis Optica Market Size by Type 2.2.1 Global Drugs for Neuromyelitis Optica Sales in Value, by Type (2017, 2022 & 2028) 2.2.2 Global Drugs for Neuromyelitis Optica Sales in Volume, by Type (2017, 2022 & 2028) 2.2.3 Global Drugs for Neuromyelitis Optica Average Selling Price (ASP) by Type (2017, 2022 & 2028) 2.3 United States Drugs for Neuromyelitis Optica Market Size by Type 2.3.1 United States Drugs for Neuromyelitis Optica Sales in Value, by Type (2017, 2022 & 2028) 2.3.2 United States Drugs for Neuromyelitis Optica Sales in Volume, by Type (2017, 2022 & 2028) 2.3.3 United States Drugs for Neuromyelitis Optica Average Selling Price (ASP) by Type (2017, 2022 & 2028) 3 Market by Application 3.1 Drugs for Neuromyelitis Optica Market Segment by Application 3.1.1 Acute Attack 3.1.2 Remission Prophylactic Treatment 3.2 Global Drugs for Neuromyelitis Optica Market Size by Application 3.2.1 Global Drugs for Neuromyelitis Optica Sales in Value, by Application (2017, 2022 & 2028) 3.2.2 Global Drugs for Neuromyelitis Optica Sales in Volume, by Application (2017, 2022 & 2028) 3.3.3 Global Drugs for Neuromyelitis Optica Average Selling Price (ASP) by Application (2017, 2022 & 2028) 3.3 United States Drugs for Neuromyelitis Optica Market Size by Application 3.3.1 United States Drugs for Neuromyelitis Optica Sales in Value, by Application (2017, 2022 & 2028) 3.3.2 United States Drugs for Neuromyelitis Optica Sales in Volume, by Application (2017, 2022 & 2028) 3.3.3 United States Drugs for Neuromyelitis Optica Average Selling Price (ASP) by Application (2017, 2022 & 2028) 4 Global Drugs for Neuromyelitis Optica Competitor Landscape by Company 4.1 Global Drugs for Neuromyelitis Optica Market Size by Company 4.1.1 Top Global Drugs for Neuromyelitis Optica Manufacturers Ranked by Revenue (2021) 4.1.2 Global Drugs for Neuromyelitis Optica Revenue by Manufacturer (2017-2022) 4.1.3 Global Drugs for Neuromyelitis Optica Sales by Manufacturer (2017-2022) 4.1.4 Global Drugs for Neuromyelitis Optica Price by Manufacturer (2017-2022) 4.2 Global Drugs for Neuromyelitis Optica Concentration Ratio (CR) 4.2.1 Drugs for Neuromyelitis Optica Market Concentration Ratio (CR) (2017-2022) 4.2.2 Global Top 5 and Top 10 Largest Manufacturers of Drugs for Neuromyelitis Optica in 2021 4.2.3 Global Drugs for Neuromyelitis Optica Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 4.3 Global Drugs for Neuromyelitis Optica Manufacturing Base Distribution, Product Type 4.3.1 Global Drugs for Neuromyelitis Optica Manufacturers, Headquarters and Distribution of Producing Region 4.3.2 Manufacturers Drugs for Neuromyelitis Optica Product Type 4.3.3 Date of International Manufacturers Enter into Drugs for Neuromyelitis Optica Market 4.4 Manufacturers Mergers & Acquisitions, Expansion Plans 4.5 United States Drugs for Neuromyelitis Optica Market Size by Company 4.5.1 Top Drugs for Neuromyelitis Optica Players in United States, Ranked by Revenue (2021) 4.5.2 United States Drugs for Neuromyelitis Optica Revenue by Players (2020, 2021 & 2022) 4.5.3 United States Drugs for Neuromyelitis Optica Sales by Players (2020, 2021 & 2022) 5 Global Drugs for Neuromyelitis Optica Market Size by Region 5.1 Global Drugs for Neuromyelitis Optica Market Size by Region: 2017 VS 2022 VS 2028 5.2 Global Drugs for Neuromyelitis Optica Market Size in Volume by Region (2017-2028) 5.2.1 Global Drugs for Neuromyelitis Optica Sales in Volume by Region: 2017-2022 5.2.2 Global Drugs for Neuromyelitis Optica Sales in Volume Forecast by Region (2023-2028) 5.3 Global Drugs for Neuromyelitis Optica Market Size in Value by Region (2017-2028) 5.3.1 Global Drugs for Neuromyelitis Optica Sales in Value by Region: 2017-2022 5.3.2 Global Drugs for Neuromyelitis Optica Sales in Value by Region: 2023-2028 6 Segment in Region Level & Country Level 6.1 North America 6.1.1 North America Drugs for Neuromyelitis Optica Market Size YoY Growth 2017-2028 6.1.2 North America Drugs for Neuromyelitis Optica Market Facts & Figures by Country (2017, 2022 & 2028) 6.1.3 United States 6.1.4 Canada 6.2 Asia-Pacific 6.2.1 Asia-Pacific Drugs for Neuromyelitis Optica Market Size YoY Growth 2017-2028 6.2.2 Asia-Pacific Drugs for Neuromyelitis Optica Market Facts & Figures by Region (2017, 2022 & 2028) 6.2.3 China 6.2.4 Japan 6.2.5 South Korea 6.2.6 India 6.2.7 Australia 6.2.8 China Taiwan 6.2.9 Indonesia 6.2.10 Thailand 6.2.11 Malaysia 6.3 Europe 6.3.1 Europe Drugs for Neuromyelitis Optica Market Size YoY Growth 2017-2028 6.3.2 Europe Drugs for Neuromyelitis Optica Market Facts & Figures by Country (2017, 2022 & 2028) 6.3.3 Germany 6.3.4 France 6.3.5 U.K. 6.3.6 Italy 6.3.7 Russia 6.4 Latin America 6.4.1 Latin America Drugs for Neuromyelitis Optica Market Size YoY Growth 2017-2028 6.4.2 Latin America Drugs for Neuromyelitis Optica Market Facts & Figures by Country (2017, 2022 & 2028) 6.4.3 Mexico 6.4.4 Brazil 6.4.5 Argentina 6.5 Middle East and Africa 6.5.1 Middle East and Africa Drugs for Neuromyelitis Optica Market Size YoY Growth 2017-2028 6.5.2 Middle East and Africa Drugs for Neuromyelitis Optica Market Facts & Figures by Country (2017, 2022 & 2028) 6.5.3 Turkey 6.5.4 Saudi Arabia 6.5.5 UAE 7 Company Profiles 7.1 Pfizer 7.1.1 Pfizer Corporation Information 7.1.2 Pfizer Description and Business Overview 7.1.3 Pfizer Drugs for Neuromyelitis Optica Sales, Revenue and Gross Margin (2017-2022) 7.1.4 Pfizer Drugs for Neuromyelitis Optica Products Offered 7.1.5 Pfizer Recent Development 7.2 Fresenius 7.2.1 Fresenius Corporation Information 7.2.2 Fresenius Description and Business Overview 7.2.3 Fresenius Drugs for Neuromyelitis Optica Sales, Revenue and Gross Margin (2017-2022) 7.2.4 Fresenius Drugs for Neuromyelitis Optica Products Offered 7.2.5 Fresenius Recent Development 7.3 Teva 7.3.1 Teva Corporation Information 7.3.2 Teva Description and Business Overview 7.3.3 Teva Drugs for Neuromyelitis Optica Sales, Revenue and Gross Margin (2017-2022) 7.3.4 Teva Drugs for Neuromyelitis Optica Products Offered 7.3.5 Teva Recent Development 7.4 Sandoz 7.4.1 Sandoz Corporation Information 7.4.2 Sandoz Description and Business Overview 7.4.3 Sandoz Drugs for Neuromyelitis Optica Sales, Revenue and Gross Margin (2017-2022) 7.4.4 Sandoz Drugs for Neuromyelitis Optica Products Offered 7.4.5 Sandoz Recent Development 7.5 Intas 7.5.1 Intas Corporation Information 7.5.2 Intas Description and Business Overview 7.5.3 Intas Drugs for Neuromyelitis Optica Sales, Revenue and Gross Margin (2017-2022) 7.5.4 Intas Drugs for Neuromyelitis Optica Products Offered 7.5.5 Intas Recent Development 7.6 Gyjtrs 7.6.1 Gyjtrs Corporation Information 7.6.2 Gyjtrs Description and Business Overview 7.6.3 Gyjtrs Drugs for Neuromyelitis Optica Sales, Revenue and Gross Margin (2017-2022) 7.6.4 Gyjtrs Drugs for Neuromyelitis Optica Products Offered 7.6.5 Gyjtrs Recent Development 7.7 NANG KUANG 7.7.1 NANG KUANG Corporation Information 7.7.2 NANG KUANG Description and Business Overview 7.7.3 NANG KUANG Drugs for Neuromyelitis Optica Sales, Revenue and Gross Margin (2017-2022) 7.7.4 NANG KUANG Drugs for Neuromyelitis Optica Products Offered 7.7.5 NANG KUANG Recent Development 7.8 Tianjin Kingyork 7.8.1 Tianjin Kingyork Corporation Information 7.8.2 Tianjin Kingyork Description and Business Overview 7.8.3 Tianjin Kingyork Drugs for Neuromyelitis Optica Sales, Revenue and Gross Margin (2017-2022) 7.8.4 Tianjin Kingyork Drugs for Neuromyelitis Optica Products Offered 7.8.5 Tianjin Kingyork Recent Development 7.9 Baxter 7.9.1 Baxter Corporation Information 7.9.2 Baxter Description and Business Overview 7.9.3 Baxter Drugs for Neuromyelitis Optica Sales, Revenue and Gross Margin (2017-2022) 7.9.4 Baxter Drugs for Neuromyelitis Optica Products Offered 7.9.5 Baxter Recent Development 7.10 CSL 7.10.1 CSL Corporation Information 7.10.2 CSL Description and Business Overview 7.10.3 CSL Drugs for Neuromyelitis Optica Sales, Revenue and Gross Margin (2017-2022) 7.10.4 CSL Drugs for Neuromyelitis Optica Products Offered 7.10.5 CSL Recent Development 7.11 Grifols 7.11.1 Grifols Corporation Information 7.11.2 Grifols Description and Business Overview 7.11.3 Grifols Drugs for Neuromyelitis Optica Sales, Revenue and Gross Margin (2017-2022) 7.11.4 Grifols Drugs for Neuromyelitis Optica Products Offered 7.11.5 Grifols Recent Development 7.12 Octapharma 7.12.1 Octapharma Corporation Information 7.12.2 Octapharma Description and Business Overview 7.12.3 Octapharma Drugs for Neuromyelitis Optica Sales, Revenue and Gross Margin (2017-2022) 7.12.4 Octapharma Products Offered 7.12.5 Octapharma Recent Development 7.13 CBOP 7.13.1 CBOP Corporation Information 7.13.2 CBOP Description and Business Overview 7.13.3 CBOP Drugs for Neuromyelitis Optica Sales, Revenue and Gross Margin (2017-2022) 7.13.4 CBOP Products Offered 7.13.5 CBOP Recent Development 8 Industry Chain and Sales Channels Analysis 8.1 Drugs for Neuromyelitis Optica Industry Chain Analysis 8.2 Drugs for Neuromyelitis Optica Key Raw Materials 8.2.1 Key Raw Materials 8.2.2 Drugs for Neuromyelitis Optica Distributors 8.3 Drugs for Neuromyelitis Optica Production Mode & Process 8.4 Drugs for Neuromyelitis Optica Sales and Marketing 8.4.1 Drugs for Neuromyelitis Optica Sales Channels 8.4.2 Drugs for Neuromyelitis Optica Distributors 8.5 Drugs for Neuromyelitis Optica Customers 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Author Details 10.3 Disclaimer

List of Tables Table 1. Drugs for Neuromyelitis Optica CAGR in Value, United States VS Global, 2017 VS 2022 VS 2028 Table 2. Drugs for Neuromyelitis Optica Market Trends Table 3. Drugs for Neuromyelitis Optica Market Drivers Table 4. Drugs for Neuromyelitis Optica Market Challenges Table 5. Drugs for Neuromyelitis Optica Market Restraints Table 6. Global Drugs for Neuromyelitis Optica Sales by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 7. United States Drugs for Neuromyelitis Optica Sales by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 8. Global Drugs for Neuromyelitis Optica Sales by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 9. United States Drugs for Neuromyelitis Optica Sales by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 10. Top Drugs for Neuromyelitis Optica Manufacturers in Global Market, Ranking by Revenue (2021) Table 11. Global Drugs for Neuromyelitis Optica Revenue by Manufacturer, (US$ Million), 2017-2022 Table 12. Global Drugs for Neuromyelitis Optica Revenue Share by Manufacturer, 2017-2022 Table 13. Global Drugs for Neuromyelitis Optica Sales by Manufacturer, (K Units), 2017-2022 Table 14. Global Drugs for Neuromyelitis Optica Sales Share by Manufacturer, 2017-2022 Table 15. Global Drugs for Neuromyelitis Optica Price by Manufacturer (2017-2022) & (US$/Unit) Table 16. Global Drugs for Neuromyelitis Optica Manufacturers Market Concentration Ratio (CR5 and HHI) Table 17. Global Drugs for Neuromyelitis Optica by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Neuromyelitis Optica as of 2021) Table 18. Top Players of Drugs for Neuromyelitis Optica in Global Market, Headquarters and Distribution of Producing Region Table 19. Manufacturers Drugs for Neuromyelitis Optica Product Type Table 20. Date of International Manufacturers Enter into Drugs for Neuromyelitis Optica Market Table 21. Manufacturers Mergers & Acquisitions, Expansion Plans Table 22. Top Drugs for Neuromyelitis Optica Players in United States Market, Ranking by Revenue (2021) Table 23. United States Drugs for Neuromyelitis Optica Revenue by Players, (US$ Million), 2020, 2021 & 2022 Table 24. United States Drugs for Neuromyelitis Optica Revenue Share by Players, 2020, 2021 & 2022 Table 25. United States Drugs for Neuromyelitis Optica Sales by Players, (K Units), 2020, 2021 & 2022 Table 26. United States Drugs for Neuromyelitis Optica Sales Share by Players, 2020, 2021 & 2022 Table 27. Global Drugs for Neuromyelitis Optica Market Size by Region (US$ Million): 2017 VS 2022 VS 2028 Table 28. Global Drugs for Neuromyelitis Optica Sales in Volume by Region (2017-2022) & (K Units) Table 29. Global Drugs for Neuromyelitis Optica Sales in Volume Forecast by Region (2023-2028) & (K Units) Table 30. Global Drugs for Neuromyelitis Optica Sales in Value by Region (2017-2022) & (US$ Million) Table 31. Global Drugs for Neuromyelitis Optica Sales in Value Forecast by Region (2023-2028) & (US$ Million) Table 32. North America Drugs for Neuromyelitis Optica Sales in Volume by Country (2017-2028) & (K Units) Table 33. North America Drugs for Neuromyelitis Optica Sales in Value by Country (2017-2028) & (US$ Million) Table 34. Asia Pacific Drugs for Neuromyelitis Optica Sales in Volume by Region (2017-2028) & (K Units) Table 35. Asia Pacific Drugs for Neuromyelitis Optica Sales in Value by Region (2017-2028) & (US$ Million) Table 36. Europe Drugs for Neuromyelitis Optica Sales in Volume by Country (2017-2028) & (K Units) Table 37. Europe Drugs for Neuromyelitis Optica Sales in Value by Country (2017-2028) & (US$ Million) Table 38. Latin America Drugs for Neuromyelitis Optica Sales in Volume by Country (2017-2028) & (K Units) Table 39. Latin Americaa Drugs for Neuromyelitis Optica Sales in Value by Country (2017-2028) & (US$ Million) Table 40. Middle East and Africa Drugs for Neuromyelitis Optica Sales in Volume by Country (2017-2028) & (K Units) Table 41. Middle East and Africa Drugs for Neuromyelitis Optica Sales in Value by Country (2017-2028) & (US$ Million) Table 42. Pfizer Corporation Information Table 43. Pfizer Description and Business Overview Table 44. Pfizer Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 45. Pfizer Drugs for Neuromyelitis Optica Product Table 46. Pfizer Recent Development Table 47. Fresenius Corporation Information Table 48. Fresenius Description and Business Overview Table 49. Fresenius Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 50. Fresenius Product Table 51. Fresenius Recent Development Table 52. Teva Corporation Information Table 53. Teva Description and Business Overview Table 54. Teva Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 55. Teva Product Table 56. Teva Recent Development Table 57. Sandoz Corporation Information Table 58. Sandoz Description and Business Overview Table 59. Sandoz Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 60. Sandoz Product Table 61. Sandoz Recent Development Table 62. Intas Corporation Information Table 63. Intas Description and Business Overview Table 64. Intas Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 65. Intas Product Table 66. Intas Recent Development Table 67. Gyjtrs Corporation Information Table 68. Gyjtrs Description and Business Overview Table 69. Gyjtrs Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 70. Gyjtrs Product Table 71. Gyjtrs Recent Development Table 72. NANG KUANG Corporation Information Table 73. NANG KUANG Description and Business Overview Table 74. NANG KUANG Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 75. NANG KUANG Product Table 76. NANG KUANG Recent Development Table 77. Tianjin Kingyork Corporation Information Table 78. Tianjin Kingyork Description and Business Overview Table 79. Tianjin Kingyork Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 80. Tianjin Kingyork Product Table 81. Tianjin Kingyork Recent Development Table 82. Baxter Corporation Information Table 83. Baxter Description and Business Overview Table 84. Baxter Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 85. Baxter Product Table 86. Baxter Recent Development Table 87. CSL Corporation Information Table 88. CSL Description and Business Overview Table 89. CSL Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 90. CSL Product Table 91. CSL Recent Development Table 92. Grifols Corporation Information Table 93. Grifols Description and Business Overview Table 94. Grifols Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 95. Grifols Product Table 96. Grifols Recent Development Table 97. Octapharma Corporation Information Table 98. Octapharma Description and Business Overview Table 99. Octapharma Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 100. Octapharma Product Table 101. Octapharma Recent Development Table 102. CBOP Corporation Information Table 103. CBOP Description and Business Overview Table 104. CBOP Drugs for Neuromyelitis Optica Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2017-2022) Table 105. CBOP Product Table 106. CBOP Recent Development Table 107. Key Raw Materials Lists Table 108. Raw Materials Key Suppliers Lists Table 109. Drugs for Neuromyelitis Optica Customers List Table 110. Drugs for Neuromyelitis Optica Distributors List Table 111. Research Programs/Design for This Report Table 112. Key Data Information from Secondary Sources Table 113. Key Data Information from Primary Sources List of Figures Figure 1. Drugs for Neuromyelitis Optica Product Picture Figure 2. Global Drugs for Neuromyelitis Optica Revenue, (US$ Million), 2017 VS 2022 VS 2028 Figure 3. Global Drugs for Neuromyelitis Optica Market Size 2017-2028 (US$ Million) Figure 4. Global Drugs for Neuromyelitis Optica Sales 2017-2028 (K Units) Figure 5. United States Drugs for Neuromyelitis Optica Revenue, (US$ Million), 2017 VS 2022 VS 2028 Figure 6. United States Drugs for Neuromyelitis Optica Market Size 2017-2028 (US$ Million) Figure 7. United States Drugs for Neuromyelitis Optica Sales 2017-2028 (K Units) Figure 8. United States Drugs for Neuromyelitis Optica Market Share in Global, in Value (US$ Million) 2017-2028 Figure 9. United States Drugs for Neuromyelitis Optica Market Share in Global, in Volume (K Units) 2017-2028 Figure 10. Drugs for Neuromyelitis Optica Report Years Considered Figure 11. Product Picture of Glucocorticoids Figure 12. Product Picture of Immunotherapies Figure 13. Product Picture of Other Figure 14. Global Drugs for Neuromyelitis Optica Market Share by Type in 2022 & 2028 Figure 15. Global Drugs for Neuromyelitis Optica Sales in Value by Type (2017-2028) & (US$ Million) Figure 16. Global Drugs for Neuromyelitis Optica Sales Market Share in Value by Type (2017-2028) Figure 17. Global Drugs for Neuromyelitis Optica Sales by Type (2017-2028) & (K Units) Figure 18. Global Drugs for Neuromyelitis Optica Sales Market Share in Volume by Type (2017-2028) Figure 19. Global Drugs for Neuromyelitis Optica Price by Type (2017-2028) & (US$/Unit) Figure 20. United States Drugs for Neuromyelitis Optica Market Share by Type in 2022 & 2028 Figure 21. United States Drugs for Neuromyelitis Optica Sales in Value by Type (2017-2028) & (US$ Million) Figure 22. United States Drugs for Neuromyelitis Optica Sales Market Share in Value by Type (2017-2028) Figure 23. United States Drugs for Neuromyelitis Optica Sales by Type (2017-2028) & (K Units) Figure 24. United States Drugs for Neuromyelitis Optica Sales Market Share in Volume by Type (2017-2028) Figure 25. United States Drugs for Neuromyelitis Optica Price by Type (2017-2028) & (US$/Unit) Figure 26. Product Picture of Acute Attack Figure 27. Product Picture of Remission Prophylactic Treatment Figure 28. Global Drugs for Neuromyelitis Optica Market Share by Application in 2022 & 2028 Figure 29. Global Drugs for Neuromyelitis Optica Sales in Value by Application (2017-2028) & (US$ Million) Figure 30. Global Drugs for Neuromyelitis Optica Sales Market Share in Value by Application (2017-2028) Figure 31. Global Drugs for Neuromyelitis Optica Sales by Application (2017-2028) & (K Units) Figure 32. Global Drugs for Neuromyelitis Optica Sales Market Share in Volume by Application (2017-2028) Figure 33. Global Drugs for Neuromyelitis Optica Price by Application (2017-2028) & (US$/Unit) Figure 34. United States Drugs for Neuromyelitis Optica Market Share by Application in 2022 & 2028 Figure 35. United States Drugs for Neuromyelitis Optica Sales in Value by Application (2017-2028) & (US$ Million) Figure 36. United States Drugs for Neuromyelitis Optica Sales Market Share in Value by Application (2017-2028) Figure 37. United States Drugs for Neuromyelitis Optica Sales by Application (2017-2028) & (K Units) Figure 38. United States Drugs for Neuromyelitis Optica Sales Market Share in Volume by Application (2017-2028) Figure 39. United States Drugs for Neuromyelitis Optica Price by Application (2017-2028) & (US$/Unit) Figure 40. North America Drugs for Neuromyelitis Optica Sales in Volume Growth Rate 2017-2028 (K Units) Figure 41. North America Drugs for Neuromyelitis Optica Sales in Value Growth Rate 2017-2028 (US$ Million) Figure 42. United States Drugs for Neuromyelitis Optica Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 43. Canada Drugs for Neuromyelitis Optica Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 44. Europe Drugs for Neuromyelitis Optica Sales in Volume Growth Rate 2017-2028 (K Units) Figure 45. Europe Drugs for Neuromyelitis Optica Sales in Value Growth Rate 2017-2028 (US$ Million) Figure 46. Germany Drugs for Neuromyelitis Optica Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 47. France Drugs for Neuromyelitis Optica Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 48. U.K. Drugs for Neuromyelitis Optica Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 49. Italy Drugs for Neuromyelitis Optica Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 50. Russia Drugs for Neuromyelitis Optica Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 51. Asia-Pacific Drugs for Neuromyelitis Optica Sales in Volume Growth Rate 2017-2028 (K Units) Figure 52. Asia-Pacific Drugs for Neuromyelitis Optica Sales in Value Growth Rate 2017-2028 (US$ Million) Figure 53. China Drugs for Neuromyelitis Optica Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 54. Japan Drugs for Neuromyelitis Optica Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 55. South Korea Drugs for Neuromyelitis Optica Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 56. India Drugs for Neuromyelitis Optica Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 57. Australia Drugs for Neuromyelitis Optica Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 58. China Taiwan Drugs for Neuromyelitis Optica Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 59. Indonesia Drugs for Neuromyelitis Optica Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 60. Thailand Drugs for Neuromyelitis Optica Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 61. Malaysia Drugs for Neuromyelitis Optica Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 62. Latin America Drugs for Neuromyelitis Optica Sales in Volume Growth Rate 2017-2028 (K Units) Figure 63. Latin America Drugs for Neuromyelitis Optica Sales in Value Growth Rate 2017-2028 (US$ Million) Figure 64. Mexico Drugs for Neuromyelitis Optica Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 65. Brazil Drugs for Neuromyelitis Optica Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 66. Argentina Drugs for Neuromyelitis Optica Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 67. Middle East & Africa Drugs for Neuromyelitis Optica Sales in Volume Growth Rate 2017-2028 (K Units) Figure 68. Middle East & Africa Drugs for Neuromyelitis Optica Sales in Value Growth Rate 2017-2028 (US$ Million) Figure 69. Turkey Drugs for Neuromyelitis Optica Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 70. Saudi Arabia Drugs for Neuromyelitis Optica Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 71. UAE Drugs for Neuromyelitis Optica Sales in Value Growth Rate (2017-2028) & (US$ Million) Figure 72. Drugs for Neuromyelitis Optica Value Chain Figure 73. Drugs for Neuromyelitis Optica Production Process Figure 74. Channels of Distribution Figure 75. Distributors Profiles Figure 76. Bottom-up and Top-down Approaches for This Report Figure 77. Data Triangulation Figure 78. Key Executives Interviewed

Pfizer Fresenius Teva Sandoz Intas Gyjtrs NANG KUANG Tianjin Kingyork Baxter CSL Grifols Octapharma CBOP